RT info:eu-repo/semantics/article
T1 Ocular delivery of polyphenols: meeting the unmet needs
A1 Krstić, Luna
A1 González García, María Jesús
A1 Diebold Luque, María Yolanda
K1 Polyphenols
K1 Farmacología ocular
K1 Oxidative stress
K1 Antioxidantes
K1 Inflammation
K1 3201.09 Oftalmología
AB Nature has become one of the main sources of exploration for researchers that search for new potential molecules to be used in therapy. Polyphenols are emerging as a class of compounds that have attracted the attention of pharmaceutical and biomedical scientists. Thanks to their structural peculiarities, polyphenolic compounds are characterized as good scavengers of free radical species. This, among other medicinal effects, permits them to interfere with different molecular pathways that are involved in the inflammatory process. Unfortunately, many compounds of this class possess low solubility in aqueous solvents and low stability. Ocular pathologies are spread worldwide. It is estimated that every individual at least once in their lifetime experiences some kind of eye disorder. Oxidative stress or inflammatory processes are the basic etiological mechanisms of many ocular pathologies. A variety of polyphenolic compounds have been proved to be efficient in suppressing some of the indicators of these pathologies in in vitro and in vivo models. Further application of polyphenolic compounds in ocular therapy lacks an adequate formulation approach. Therefore, more emphasis should be put in advanced delivery strategies that will overcome the limits of the delivery site as well as the ones related to the polyphenols in use. This review analyzes different drug delivery strategies that are employed for the formulation of polyphenolic compounds when used to treat ocular pathologies related to oxidative stress and inflammation.
PB MDPI
SN 1420-3049
YR 2021
FD 2021
LK https://uvadoc.uva.es/handle/10324/55631
UL https://uvadoc.uva.es/handle/10324/55631
LA eng
NO Molecules,  2021,Vol. 26, Nº.2, 370, 26 pp.
NO Producción Científica
DS UVaDOC
RD 25-nov-2024